SEC Form 4 · accession 0000899243-15-003640
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J Williams Ph.D.
Officer — Executive Vice President
Period of report
Aug 18, 2015
Accepted (ET)
Aug 20, 2015 · 1:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 18, 2015 | M | 6,586 | $26.66 | A | 36,672 | D | |
| Common StockF1 | Aug 18, 2015 | S | 6,586 | $78.34 | D | 30,086 | D | |
| Common Stock | Aug 18, 2015 | M | 3,750 | $26.66 | A | 33,836 | D | |
| Common Stock | Aug 18, 2015 | M | 5,818 | $17.19 | A | 39,654 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to buy)F2 | $26.66 | Aug 18, 2015 | M | 6,586 | D | — | Feb 13, 2017 | Common Stock | 6,586 | 0 | D |
| Incentive Stock Option (Right to buy)F3 | $26.66 | Aug 18, 2015 | M | 3,750 | D | — | Feb 13, 2017 | Common Stock | 3,750 | 0 | D |
| Incentive Stock Option (Right to buy)F4 | $17.19 | Aug 18, 2015 | M | 5,818 | D | — | Feb 13, 2016 | Common Stock | 5,818 | 0 | D |
Explanation of responses
- F1The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $78.33 to $78.40, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- F2Grant of option to buy shares of IDEXX Laboratories Inc. common stock that became exercisable as to 3,834 shares on 2/14/2011, 2/14/2012, 2/14/2013 and 2/14/2014 and the remaining 1,959 shares on 2/14/2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F3Grant of option to buy 1,875 shares of IDEXX Laboratories, Inc. common stock that became exercisable on the fifth anniversary date (2/14/2015) of the date of grant, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F4Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 1 share on 02/14/2010 and 02/14/2013 and the remaining 2,909 shares on 02/14/2014, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.